US Patent 6,946,120: Minoxidil Foam Claims, Patent Scope, Expiration and Generic Risk

US Patent 6,946,120 protected acidic, homogeneous minoxidil aerosol foams and mousses containing at least about 5% minoxidil, water, a lower alcohol, an acid solubilizer and limited polyhydric alcohol. The patent also covered topical treatment of hair loss with the formulation and an aerosol package containing a suitable propellant.

The patent’s nominal term ended in 2021. It is therefore not an active barrier to current U.S. commercialization, although it remains relevant to historical Rogaine foam exclusivity, formulation design, litigation analysis and prior-art review. The patent was not an Orange Book-listed drug patent because topical minoxidil foam is marketed under the FDA’s nonprescription OTC framework rather than an approved prescription NDA.

What does US Patent 6,946,120 protect?

The patent protects a specific formulation architecture rather than minoxidil generally.

The core formulation requires:

Limitation	Scope under the issued claims
Active ingredient	Minoxidil or a pharmaceutically acceptable salt
Minoxidil concentration	Approximately 5% or greater in claim 1; narrower ranges appear in claims 3, 4, 13 and 14-18
Solubilizer	Mineral or organic acid selected from the claimed lists
Solvent	Water and a lower alcohol
Water-to-alcohol ratio	Approximately 9:1 to 1:9 by volume
Co-solvent	Selected polyhydric alcohol, generally below approximately 10%
Dosage form	Homogeneous aerosol formulation producing a foam or mousse
Additional formulation limitations	pH, acid normality, ethanol, propylene glycol, fatty alcohols, polysorbate 60 and antioxidants
Therapeutic use	Topical treatment of hair loss and related indications
Delivery system	Formulation combined with a suitable propellant

The claims do not cover every topical minoxidil product. A product outside the claimed concentration, acid, solvent ratio, dosage form or excipient limitations would not literally satisfy the independent formulation claims.

What are the independent claims in US 6,946,120?

Claims 1, 14, 18, 19, 20 and 21 are the principal independent claims.

Claim 1: broadest formulation claim

Claim 1 requires a homogeneous aerosol formulation consisting essentially of:

at least approximately 5% minoxidil or a pharmaceutically acceptable salt;
an acid capable of solubilizing the minoxidil;
a specified mineral or organic acid;
water and a lower alcohol in a 9:1 to 1:9 volume ratio;
less than approximately 10% of a listed polyhydric alcohol; and
a final foam or mousse product.

The acid list includes hydrochloric, sulfuric, nitric and phosphoric acids, together with citric, acetic, succinic, maleic, benzoic and lactic acids.

The phrase “consisting essentially of” is significant. It permits additional ingredients that do not materially alter the formulation’s basic characteristics, but it can exclude ingredients that materially change the homogeneous, solubilized aerosol foam system. In an infringement analysis, the effect of an unlisted excipient would matter more than its mere presence.

Claim 14: approximately 5% minoxidil and propylene glycol

Claim 14 narrows the formulation to approximately 5% minoxidil and requires:

water;
ethanol;
less than approximately 10% propylene glycol;
the claimed acid system; and
a water-to-alcohol ratio from approximately 9:1 to 1:9.

This claim is directed more specifically to a 5% minoxidil foam using ethanol and propylene glycol rather than the broader list of polyhydric alcohols in claim 1.

Claim 18: fatty alcohol and surfactant system

Claim 18 requires:

approximately 5% minoxidil;
water and ethanol;
the claimed acid;
cetyl alcohol;
stearyl alcohol;
polysorbate 60;
no more than approximately 5% propylene glycol; and
a foam or mousse.

This claim adds a structured fatty-alcohol and surfactant package. The combination is materially narrower than claim 1 and is more vulnerable to design-around through changes in emulsifier, surfactant, fatty alcohol or propylene glycol concentration.

Claim 19: treatment method

Claim 19 covers applying an infringing formulation to the human scalp for treatment or prevention of hair loss. It also requires a foam or mousse that “breaks with shear.”

The shear-breaking limitation is functional and technically important. It distinguishes a foam that collapses or liquefies during application from a persistent foam that remains structurally stable after dispensing. Product testing would likely focus on dispensing behavior, foam stability, shear response and residue.

Claim 20: aerosol package

Claim 20 covers a formulation within the preceding formulation claims combined with a suitable propellant. The claim is directed to the packaged aerosol system rather than merely the bulk liquid concentrate.

Claim 21: antioxidant-containing formulation

Claim 21 repeats the narrow fatty-alcohol and surfactant structure of claim 18 and adds an antioxidant. The antioxidant is not restricted to a named compound in the claim, which creates a broader functional category but leaves the claim dependent on all of the other formulation limitations.

How do the dependent claims narrow the patent?

The dependent claims establish multiple fallback positions.

Claims	Added limitation
2	Apparent pH approximately 7.0 or less
3	Minoxidil approximately 5% to 25%
4	Minoxidil approximately 7.5% to 12%
5	Apparent pH approximately 5.0 to 7.0
6	Acetic acid or lactic acid
7	Lower alcohol is ethanol
8	Water-to-ethanol ratio approximately 1:1 to 1:3
9	Glycerol, 1,3-butylene glycol or propylene glycol
10	Acid provides at least 0.01 N acid
11	Acid molar amount at least equal to minoxidil in normal amounts
12	Minoxidil acetate or minoxidil lactate
13	Specific composition ranges for minoxidil, water, ethanol and propylene glycol
15	Propylene glycol approximately 5% or less
16	Water approximately 24%-33% and ethanol approximately 43%-60%
17	Acid is lactic acid

Claim 13 is commercially important because it describes a practical 5%-12% minoxidil foam composition with approximately 24%-33% water, 43%-60% ethanol and less than 10% propylene glycol. Claims 15-17 further narrow the 5% propylene glycol and water/ethanol ranges.

What formulation elements create the main infringement risk?

A competing product would present the highest historical literal-infringement risk when it has the following profile:

Minoxidil at 5% or more.
An acidic formulation using one of the listed acids.
Water and ethanol.
A water-to-ethanol ratio between approximately 9:1 and 1:9.
Propylene glycol below approximately 10%.
A homogeneous aerosol foam or mousse.
A suitable propellant.
Fatty alcohols and polysorbate 60, if claims 18 or 21 are asserted.
Foam that breaks or collapses with shear, if claim 19 is asserted.

A conventional liquid minoxidil solution would normally avoid the aerosol-foam limitation. A non-aqueous product, a product using a solvent ratio outside the claimed range, or a formulation using a nonlisted acid would reduce literal coverage risk.

The patent’s “approximately” language introduces numerical tolerance. The relevant question would not be whether a formulation is exactly 5.000% minoxidil or exactly 1:3 water to ethanol. The analysis would consider claim construction, experimental variability, prosecution history and whether the accused value performs substantially the same function within the claimed approximation.

How strong was the patent estate for minoxidil foam?

The patent was technically focused but commercially meaningful during its term.

Strengths

The claims linked several formulation parameters that are difficult to separate in a commercial foam:

high minoxidil loading;
acid-assisted solubilization;
a water/alcohol solvent system;
controlled polyhydric alcohol content;
aerosol foam delivery; and
scalp application.

The patent also included multiple formulation, method and packaging claim types. That structure could support different infringement theories against a finished product, a bulk formulation supplier and an aerosol package manufacturer.

Limitations

The claims were narrow in several respects:

The acid had to fall within an express list.
The formulation had to be homogeneous.
The final product had to be a foam or mousse.
The minoxidil concentration generally had to be at least approximately 5%.
Several claims required propylene glycol, ethanol or particular fatty alcohols.
Claims 18 and 21 required cetyl alcohol, stearyl alcohol and polysorbate 60.

The claim set therefore did not create a broad monopoly over minoxidil topical therapy, 5% minoxidil generally or all foam dosage forms.

When did US Patent 6,946,120 lose exclusivity?

The patent’s nominal U.S. term ended in 2021, calculated from the relevant international or U.S. filing chronology under the 20-year patent-term rule. The patent is no longer an enforceable exclusivity right against current U.S. products.

Historical infringement claims would remain subject to the six-year damages limitation in 35 U.S.C. § 286. Patent expiration eliminates prospective injunctive exclusivity, but it does not automatically eliminate every claim relating to conduct occurring before expiration.

The patent should therefore be classified as:

Issue	Status
U.S. patent	Expired
Current blocking right	No
Historical relevance	High for pre-2021 products and litigation
Orange Book exclusivity	No
Current Paragraph IV risk	None under this expired patent
Current generic launch barrier	None from this patent
Formulation design-around value	Still relevant as prior art

USPTO Patent Center and the USPTO Patent Examination Data System are the controlling sources for the official prosecution and term record. The public patent record identifies the patent as a minoxidil foam patent issued to The Boots Company PLC. [1]

What is the Orange Book status of US 6,946,120?

US 6,946,120 is not an Orange Book-listed patent for an approved prescription drug product.

The Orange Book identifies patents and regulatory exclusivities associated with approved drug applications. Rogaine and other topical minoxidil products are generally marketed as OTC products under FDA’s topical minoxidil regulatory framework rather than through a prescription NDA that would generate a conventional Orange Book patent listing. [2]

This has several consequences:

An ANDA Paragraph IV challenge would not be the normal pathway for attacking this patent.
The patent’s expiration did not itself trigger an ANDA market opening.
Generic and private-label competition can enter through the applicable OTC framework, subject to FDA requirements.
Patent disputes would more likely involve ordinary infringement litigation, contract rights, trademark rights or regulatory compliance rather than Orange Book certification.

Were Paragraph IV challenges or settlements required?

No conventional Paragraph IV process was required for this patent.

Paragraph IV certifications apply to patents listed in the Orange Book for an approved reference listed drug. Because topical minoxidil foam is not ordinarily positioned through an NDA-based Orange Book listing, competitors would not normally need to certify under Paragraph IV against US 6,946,120.

Publicly available regulatory and patent records do not establish a material Paragraph IV settlement involving this patent. The more relevant historical commercial issue was licensing and brand competition around minoxidil foam products, not an ANDA settlement structure.

What licensing and commercial arrangements affected minoxidil foam?

The patent was associated with The Boots Company PLC, while branded Rogaine commercialization has involved Johnson & Johnson consumer-health entities and other regional licensees or distributors over time.

Patent ownership, product commercialization and trademark ownership were not necessarily held by the same entity. A patent license could therefore affect commercial freedom even where a company did not own the patent. Current launch analysis must separate:

patent rights;
product formulation know-how;
aerosol-container and valve technology;
trademark rights;
FDA OTC compliance; and
distribution or supply agreements.

The expiration of US 6,946,120 removed the patent barrier but did not eliminate possible contractual, trademark or trade-secret restrictions.

How does US 6,946,120 compare with other minoxidil patent categories?

Patent category	Typical subject matter	Relevance after 2021
Composition patents	Minoxidil, acids, solvents and foam excipients	US 6,946,120 is expired
Method-of-use patents	Treating androgenetic alopecia or hair loss	Often limited by prior art and expiration
Aerosol package patents	Valve, actuator, propellant and container design	May remain active independently
Manufacturing patents	Mixing, filling, emulsification and foam production	Can create separate process risk
OTC regulatory exclusivity	FDA monograph or approved application rights	Separate from patent term
Trademark rights	Rogaine and related branding	Can remain active indefinitely with use
Trade secrets	Manufacturing parameters and stability data	Potentially continuing if secret

A product can avoid US 6,946,120 while still implicating a separate active patent covering its container, valve, manufacturing process or delivery technology.

What generic launch scenarios existed after expiration?

After patent expiration, the principal launch scenarios were:

Direct OTC monograph launch

A manufacturer could develop a 5% minoxidil foam conforming to applicable FDA OTC requirements and avoid reliance on an expired patent. The product would still require compliant labeling, manufacturing controls, stability data and packaging.

Private-label launch

A retailer or consumer-health company could source a finished foam from a contract manufacturer. The patent risk would be reduced to zero for US 6,946,120 after expiration, but supply-chain indemnities and separate device patents would remain relevant.

Formulation design-around

A company could use:

a different acid;
a different solvent ratio;
a non-aerosol pump foam;
a different surfactant system;
a different co-solvent;
a different minoxidil concentration; or
a non-homogeneous suspension or emulsion.

During the patent term, these changes would have reduced literal infringement exposure. After expiration, their primary value is technical differentiation, stability performance and freedom from other patents.

What geographic coverage did the patent provide?

US 6,946,120 provided rights only in the United States. Foreign family members, if granted, required separate analysis by country and could have different claims, expiration dates, prosecution histories and legal status.

A U.S. expiry did not automatically terminate corresponding rights in Europe, Canada, Australia or other jurisdictions. For a global launch, the relevant analysis must identify each national family member and confirm whether the corresponding right expired, lapsed, was revoked, abandoned or remained enforceable.

What manufacturing and intellectual-property barriers remain?

The expired patent no longer blocks manufacture of the claimed formulation in the United States. Current barriers may still include:

validated mixing and acidification processes;
minoxidil solubilization and crystallization control;
foam density and collapse performance;
aerosol valve compatibility;
propellant selection;
can corrosion and extractables;
preservative and antioxidant stability;
microbial control;
filling and crimping equipment;
container-closure integrity;
OTC labeling compliance; and
active patents covering packaging or manufacturing.

The patent’s technical disclosure remains useful as prior art when assessing newer applications claiming minoxidil foam compositions, aerosol systems or related scalp-treatment formulations.

Key Takeaways

US 6,946,120 covered acidic, homogeneous minoxidil aerosol foams and mousses.
The central formulation required at least approximately 5% minoxidil, a listed acid, water and lower alcohol, a defined solvent ratio and limited polyhydric alcohol.
Claims 14, 18 and 21 narrowed the invention to propylene glycol, fatty alcohols, polysorbate 60 and antioxidant systems.
Claim 19 covered topical scalp treatment with a shear-breaking foam.
Claim 20 covered the formulation combined with a propellant.
The patent expired in 2021 and is not a current U.S. launch barrier.
It was not an Orange Book-listed patent, so Paragraph IV certification and ANDA settlement analysis are generally inapplicable.
Separate patents covering aerosol packaging, valves, manufacturing or related formulations require independent review.
The patent remains relevant as historical prior art and for pre-expiration infringement analysis.

FAQs

Is US 6,946,120 still enforceable against a 5% minoxidil foam?

No. The patent’s U.S. term ended in 2021. A current 5% minoxidil foam cannot be blocked by this expired patent alone.

Did US 6,946,120 cover Rogaine foam specifically?

The claims covered formulation characteristics consistent with commercial minoxidil foam products, but a patent claim does not depend on the brand name. Coverage turns on the product’s composition, dosage form and package limitations.

Does a 5% minoxidil liquid infringe US 6,946,120?

Not after expiration. During the patent term, a conventional liquid would generally avoid the aerosol foam limitations, subject to the exact product and any other asserted patent.

Are minoxidil foam products subject to biosimilar competition?

No. Minoxidil is a small-molecule drug, not a biologic. Biosimilar regulations do not apply. Competition proceeds through OTC drug and private-label pathways rather than the biosimilar approval route.

Can a company sell a minoxidil mousse with a different propellant?

Yes, US 6,946,120 is expired. During its term, a different propellant would not necessarily avoid claim 20 if the product still contained a claimed formulation and a suitable propellant. Separate packaging or aerosol patents could still matter.

References

United States Patent and Trademark Office. (2005). U.S. Patent No. 6,946,120, Minoxidil foam. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Over-the-counter topical minoxidil drug products; regulatory framework and labeling requirements. U.S. Department of Health and Human Services.
United States Congress. (2023). 35 U.S.C. §§ 154, 271 and 286. United States Code.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	PP 3107	Apr 22, 1998

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	331517	⤷ Start Trial
Australia	3323299	⤷ Start Trial
Australia	757601	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,946,120

Summary for Patent: 6,946,120